SCHEDULE 13D/A 0001513162-15-000408 0001191905 XXXXXXXX LIVE 8 Common Stock 06/04/2025 false 0000715446 03528H109 Anixa Biosciences Inc

3150 ALMADEN EXPRESSWAY SUITE 250 SAN JOSE CA 95118

Amit Kumar 408-708-9808 c/o Anixa Biosciences, Inc. 3150 Almaden Expressway, Suite 250 San Jose CA 95118 0001191905 N Amit Kumar PF N X1 6173097.00 0.00 6173097.00 0.00 6173097.00 N 16.3 IN Common Stock Anixa Biosciences Inc 3150 ALMADEN EXPRESSWAY SUITE 250 SAN JOSE CA 95118 16.3% 6,173,097 shares, consisting of: (i) 569,925 shares of common stock held directly and (ii) 5,603,172 shares of common stock issuable upon exercise of stock options held directly by Reporting Person and exercisable within 60 days. As of the date hereof, Dr. Kumar beneficially owns 6,173,097 shares of the Issuer, consisting of 569,925 shares of common stock held directly and 5,603,172 shares of common stock issuable upon exercise of stock options held directly and exercisable within 60 days. Such shares represent a total of 16.3% of the Issuer's outstanding shares of common stock, an increase from the 15.1% reported on Dr. Kumar's Amendment No. 7 to Schedule 13D. The change in ownership is the result of market purchases, the vesting of previously outstanding stock options and a change in the number of stock options that are not yet exercisable but will be exercisable within 60 days. The triggering event for this filing was Dr. Kumar's purchase of 10,000 shares of common stock on June 4, 2025. Dr. Kumar has the sole power to vote or direct the vote of, and to dispose or direct the disposition of, the entirety of the number of shares indicated immediately above. There are no other persons known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities. Amit Kumar /s/Amit Kumar 06/06/2025